Literature DB >> 25116104

FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.

Dilip K Challa1, Ramraj Velmurugan, Raimund J Ober, E Sally Ward.   

Abstract

The neonatal Fc receptor, FcRn, is related to MHC class I with respect to its structure and association with β2microglobulin (β2m). However, by contrast with MHC class I molecules, FcRn does not bind to peptides, but interacts with the Fc portion of IgGs and belongs to the Fc receptor family. Unlike the 'classical' Fc receptors, however, the primary functions of FcRn include salvage of IgG (and albumin) from lysosomal degradation through the recycling and transcytosis of IgG within cells. The characteristic feature of FcRn is pH-dependent binding to IgG, with relatively strong binding at acidic pH (<6.5) and negligible binding at physiological pH (7.3-7.4). FcRn is expressed in many different cell types, and endothelial and hematopoietic cells are the dominant cell types involved in IgG homeostasis in vivo. FcRn also delivers IgG across cellular barriers to sites of pathogen encounter and consequently plays a role in protection against infections, in addition to regulating renal filtration and immune complex-mediated antigen presentation. Further, FcRn has been targeted to develop both IgGs with extended half-lives and FcRn inhibitors that can lower endogenous antibody levels. These approaches have implications for the development of longer lived therapeutics and the removal of pathogenic or deleterious antibodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25116104     DOI: 10.1007/978-3-319-07911-0_12

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  28 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Authors:  Bing-Bing Yang; Sameer Doshi; Karen Arkam; Janet Franklin; Andrew T Chow
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

3.  Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Authors:  Yao-Yun Fan; Lindsay B Avery; Mengmeng Wang; Denise M O'Hara; Sheldon Leung; Hendrik Neubert
Journal:  MAbs       Date:  2016-04-22       Impact factor: 5.857

4.  Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Authors:  Lindsay B Avery; Jason Wade; Mengmeng Wang; Amy Tam; Amy King; Nicole Piche-Nicholas; Mania S Kavosi; Steve Penn; David Cirelli; Jeffrey C Kurz; Minlei Zhang; Orla Cunningham; Rhys Jones; Brian J Fennell; Barry McDonnell; Paul Sakorafas; James Apgar; William J Finlay; Laura Lin; Laird Bloom; Denise M O'Hara
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

Review 5.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

6.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

Review 7.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Authors:  Jonathan T Sockolosky; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2015-02-19       Impact factor: 15.470

Review 8.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

Review 9.  Nanotechnology for protein delivery: Overview and perspectives.

Authors:  Mikyung Yu; Jun Wu; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2015-10-13       Impact factor: 9.776

10.  Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Authors:  Peter Ulrichts; Antonio Guglietta; Torsten Dreier; Tonke van Bragt; Valérie Hanssens; Erik Hofman; Bernhardt Vankerckhoven; Peter Verheesen; Nicolas Ongenae; Valentina Lykhopiy; F Javier Enriquez; JunHaeng Cho; Raimund J Ober; E Sally Ward; Hans de Haard; Nicolas Leupin
Journal:  J Clin Invest       Date:  2018-07-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.